Merck & Co Inc (NYSE:MRK) announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial of Keytruda for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma. The data are being presented for the first time at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium. At the trial’s first pre-specified interim analysis, after a median follow-up of 22.3 months, Keytruda demonstrated a statistically significant and clinically meaningful improvement i…
